U.K.-based Renovo saw its share price soar on opening day as investors rushed to buy stock. Renovo raised about £50 million, which will go to support its programs for new therapies to prevent scarring. Its lead drug Juvista has wrapped two mid-stage clinical trials.
- here's a Telegraph report [1] on the offering
Links:
[1] http://www.telegraph.co.uk/money/main.jhtml?xml=/money/2006/04/07/urenovo.xml&sSheet=/money/2006/04/07/ixcitytop.html